Concanamycin A (high purity)

CHF 85.00
In stock
BVT-0237-C02525 µgCHF 85.00
BVT-0237-C100100 µgCHF 145.00
BVT-0237-M0011 mgCHF 335.00
BVT-0237-M0055 mgCHF 1'500.00
More Information
Product Details
Synonyms Folimycin; Antibiotic TAN 1323B; Antibiotic X4357B
Product Type Chemical
Formula C46H75NO14
MW 866.1
CAS 80890-47-7
RTECS CB9732000
Source/Host Chemicals Isolated from Streptomyces sp.
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in methanol, DMSO or acetonitrile; insoluble in water.
Identity Determined by 1H-NMR.
Declaration Manufactured by BioViotica.
Smiles [H][C@@]1(C[C@@H](O)[C@H](OC(N)=O)[C@@H](C)O1)O[C@@H]1C[C@@](O)(O[C@H](\C=C\C)[C@H]1C)[C@@H](C)[C@H](O)[C@H](C)[C@]1([H])OC(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)CC(C)=C\C=C\[C@@H]1OC
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light when in solution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
After reconstitution protect from light at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Antibiotic.
  • More potent and specific H+-ATPase inhibitor than bafilomycin A1 (Prod. No. BVT-0252).
  • Inhibits acidification of organelles such as lysosomes and the Golgi apparatus.
  • Inhibitor of autophagic degradation by rising lysosomal pH and thus inactivating the lysosomal acid hydrolases.
  • Blocks cell surface expression of viral glycoproteins without affecting their synthesis.
  • Cytotoxic in a number of cell lines in a cell viability assay.
  • Induces nitric oxide (NO) production.
  • Concanamycin A enables the immune system to kill HIV-infected cells. Nef is an HIV-encoded accessory protein that enhances pathogenicity by down-regulating major histocompatibility class I (MHC-I) expression to evade killing by cytotoxic T lymphocytes (CTLs). Concanamycin A has been identified as potent inhibitor of Nef that restores MHC-I and enhances the clearance of HIV-infected primary cells by cytotoxic T lymphocytes. Concanamycin A counteracts Nef from diverse clades of HIV targeting multiple allotypes of MHC-I, indicating the potential for broad therapeutic utility.
Product References
  1. Isolation and characterization of concanamycins A, B and C: H. Kinashi, et al.; J. Antibiot. 37, 1333 (1984)
  2. Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus: M. Muroi, et al.; Cell Struct. Funct. 18, 139 (1993)
  3. Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins: M. Muroi, et al.; BBRC 193, 999 (1993)
  4. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases: S. Drose, et al.; Biochemistry 32, 3902 (1993)
  5. Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells: M. Yilla, et al.; J. Biol. Chem. 268, 19092 (1993)
  6. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells: F.J. Sharom, et al.; Biochem. J. 308 (Pt2), 381 (1995)
  7. Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death: T. Nishihara, et al.; BBRC 212, 255 (1995)
  8. Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c: M. Huss, et al.; J. Biol. Chem. 277, 40544 (2002)
  9. Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells: J. Hong, et al.; J. Pharmacol. Exp. Ther. 319, 672 (2006)
  10. Degradation of oxidized proteins by autophagy during oxidative stress in Arabidopsis: Y. Xiong, et al.; Plant Physiol. 143, 291 (2007)
  11. Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory-pathway proteins: J.A. Sobota, et al.; J. Cell Sci. 122, 3542 (2009)
  12. Inhibitors of V-ATPase: old and new players: M. Huss, et al.; J. Exp. Biol. 212, 341 (2009)
  13. Increased production of reactive oxygen species by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A in RAW 264 cells: A. Yokomakura, et al.; J. Toxicol. Sci. 37, 1045 (2012)
  14. Inhibition of vacuolar ATPase attenuates the TRAIL-induced activation of caspase-8 and modulates the trafficking of TRAIL receptosomes: V. Horova, et al.; FEBS J. 280, 3436 (2013)
  15. Estimating the rotation rate in the vacuolar proton-ATPase in native yeast vacuolar membranes: Z. Ferencz, et al.; Eur. Biophys. J. 42, 147 (2013)
  16. Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion: V. Michel, et al.; Int. J. Cancer 132, E1 (2013)
  17. Loss of vacuolar H+-ATPase activity in organelles signals ubiquitination and endocytosis of the yeast plasma membrane proton pump Pma1p: A. M. Smardon & P. M. Kane; J. Biol. Chem. 289, 32316 (2014)
  18. Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells: H. Jin, et al.; Toxicol. Appl. Pharm. 278, 17 (2015)
  19. Appropriate vacuolar acidification in Saccharomyces cerevisiae is associated with efficient high sugar fermentation: T.D. Nguyen, et al.; Food Microbiology 70, 262 (2018)
  20. Concanamycin A counteracts HIV-1 Nef to enhance immune clearance of infected primary cells by cytotoxic T lymphocytes: M.M. Painter, et al.; PNAS 117,  23835 (2020)
  21. The V-type ATPase enhances photosynthesis in marine phytoplankton and further links phagocytosis to symbiogenesis: D.P. Yee, et al.; Curr. Biol. in press (2023)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.